SCHEMBL30765734

SCHEMBL30765734

O=CCCCc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.54
LTA4H P09960 4/20 0.48
PLAAT3 P53816 2/20 0.48
PLAAT5 Q96KN8 2/20 0.48
PLAAT2 Q9NWW9 2/20 0.48
PLAAT4 Q9UL19 2/20 0.48
SRD5A2 P31213 3/20 0.47
FDFT1 P37268 1/20 0.47
PPARG P37231 1/20 0.47
FFAR4 Q5NUL3 2/20 0.46
EPHX2 P34913 1/20 0.46
MMP12 P39900 1/20 0.43
MMP13 P45452 1/20 0.43
TSHR P16473 1/20 0.43
DAO P14920 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185148 0.89 FFAR1 (0.58) FFAR1LTA4HPLAAT3PLAAT5PLAAT2
SCHEMBL8618603 0.85 FDFT1 (0.51) FFAR1FDFT1DAO
SCHEMBL19322272 0.82 FFAR1 (0.62) FFAR1LTA4HPLAAT3PLAAT5PLAAT2
SCHEMBL2201304 0.82 FFAR1 (0.62) FFAR1LTA4HPLAAT3PLAAT5PLAAT2
SCHEMBL66826 0.82 SIGMAR1 (0.54)
SCHEMBL7300705 0.81 LTA4H (0.64) FFAR1LTA4HFFAR4EPHX2
SCHEMBL11057347 0.81 SIGMAR1 (0.52)
SCHEMBL19322269 0.81 FFAR1 (0.60) FFAR1LTA4HPLAAT3PLAAT5PLAAT2
SCHEMBL11050330 0.81 SIGMAR1 (0.52)
SCHEMBL19322285 0.81 FFAR1 (0.60) FFAR1LTA4HPLAAT3PLAAT5PLAAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed